1	High Initial Heart Rate Score is an Independent Predictor of New Atrial High-Rate			
2	Episodes in Pacemaker Patients with Sinus Node Dysfunction			
3				
4	Katsuhide Hayashi, MD <sup>#</sup> , Haruhiko Abe, MD <sup>\$</sup> , Brian Olshansky, MD*, Arjun D. Sharma,			
5	MD <sup>₱</sup> , Paul W. Jones, MS <sup>*</sup> , Nicholas Wold, MS <sup>*</sup> , David Perschbacher, BS <sup>*</sup> , Ritsuko Kohno,			
6	MD <sup>\$</sup> , Gregory Y. H. Lip MD <sup>†</sup> , Bruce L. Wilkoff, MD <sup>#</sup>			
7				
8	From			
9	<sup>#</sup> Cleveland Clinic, Cleveland, Ohio, <sup>\$</sup> University of Occupational and Environmental Health,			
10	Japan, Kitakyushu, Japan, *University of Iowa Hospital and Clinics, Iowa City, Iowa,			
11	<sup><math>\mathbb{P}</math></sup> Unaffiliated, Reno, Nevada, <sup>*</sup> Boston Scientific, St. Paul, Minnesota and <sup>†</sup> Liverpool Centre			
12	for Cardiovascular Science at University of Liverpool, Liverpool John Moores University			
13	and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Danish Center for			
14	Health Services Research, Department of Clinical Medicine, Aalborg University, Aalborg,			
15	Denmark.			
16				
17	Short Title: Heart Rate Score and Atrial High-Rate Episodes			
18				
19				
20	Word count: 3,734			
21	Abstract word count: 245			
22	Number of tables: 6; Number of figures: 3			
23				
24	Keywords: Atrial fibrillation, Pacemaker, Outcomes, Rate responsive pacing			
25				
26				
27				
28	Address for Correspondence:			
29	Katsuhide Hayashi MD			
30	9500 Euclid Avenue Cleveland, Ohio 44195			
31	Email: hayashikatsuhide11111@yahoo.co.jp			
32	Phone: 216-808-1681			
33	ORCID: 0000-0001-7269-9808			
34				
35	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.			

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

### 1 Abstract Background: Heart Rate Score (HRSc), the percent of atrial beats in the largest paced/sensed $\mathbf{2}$ 10-bpm histogram bin recorded in cardiac devices, is a metric of chronotropic incompetence. 3 It remains uncertain if HRSc independently predicts atrial high-rate episodes (AHREs) in 4 patients with sinus node dysfunction (SND) undergoing pacemaker (PM) implantation. $\mathbf{5}$ **Objective:** To determine the relationship between initial HRSc post-PM implant and 6 $\overline{7}$ new-onset AHREs in patients with SND. 8 Methods: The cohort included patients with Boston Scientific PMs implanted for SND from 2012-2021 at Cleveland Clinic, University of Occupational and Environmental Health, Japan, 9 Kyushu Rosai Hospital, and JCHO Kyushu Hospital. Patients were excluded if they had atrial 10 fibrillation before PM implant or AHREs in the initial 3-months post-implant. Subsequent 11 12AHREs post-implant (>1% of atrial beats>170 bpm) were evaluated. 13**Results:** Over 48.9 (IQR 25.8-50.4) months, 136 consecutive PM patients (age 75±10 years, 42% male) were followed. The median initial HRSc was 73(55-86)%. AHREs developed in 1428/136 (21%). Although %RA pacing and HRSc correlated, rate-responsive pacing was 1516associated with a HRSc only in the patients with high %RA pacing. Patients with HRSc≥80% had higher occurrence of AHREs than those with HRSc<80% (p=0.01, log-rank test). After 17adjusting for age, race, comorbidities, left ventricular ejection fraction, left atrial 18 19diameter, %RA/RV pacing, and rate-response programming, HRSc (HR:2.84, 95% CI:1.17-6.92; P=0.02) and male sex (HR:2.55, 95% CI:1.15-6.19; P=0.04) were independent 2021predictors of AHREs. 22**Conclusion:** HRSc>80% independently predicted new-onset, device-determined AHREs for 23patients undergoing PM implant for SND. HRSc may have prognostic and therapeutic 24implications. 2526

Heart Rate Score and Atrial High-Rate Episodes

*February* 5, 2024

### Introduction 1

Heart Rate Score (HRSc) is a novel parameter of chronotropic incompetence using  $\mathbf{2}$ 3 long-term heart rate variation for patients with cardiac implantable electronic devices (CIEDs).<sup>1</sup> It is defined as the percent of atrial beats in the largest paced/sensed 4  $\mathbf{5}$ 10-beat/minutes histogram bin of a pacemaker (PM) or implantable cardioverter-defibrillator (ICD) (Figure 1). HRSc  $\geq$ 70% predicts mortality in patients without atrial fibrillation (AF) 6 who have ICDs<sup>2</sup> or cardiac resynchronization therapy defibrillators (CRT-Ds).<sup>3,4</sup> 7

Atrial high-rate episodes (AHREs) have attracted much attention in anticoagulant 8 therapy decisions for the risk of stroke in CIED patients.<sup>5,6</sup> Unfortunately, no established data 9 from electrocardiograms or device interrogation can yet predict development of AHREs. We 10 recently showed that HRSc, early post-implantation, can predict new-onset AHREs in PM 11 patients in a large database.<sup>7</sup> In this prior study, the incidence of AHREs, defined as >1% of 12atrial beats  $\geq 170$  bpm (primary endpoint), correlated with the incidence of mode switch 1314episodes  $\geq$ 24 hours. However, that study could not collect clinical information, including PM indication, as it used a retrospective, de-identified, database. Therefore, it remains uncertain 1516whether HRSc predicts AHREs in PM patients with sinus node dysfunction (SND)

- independent of clinical parameters. 17
- The goal of this study was to evaluate the baseline HRSc post-PM implant in lieu 18of clinical characteristics and determine if an independent relationship exists between the 1920initial HRSc and subsequent development of AHREs in patients with SND who underwent 21dual-chamber PM implant. We focused on the incidence of AHREs developing after implant for those with no AHREs during an initial 3-month observation. 22
- Methods 23

### Study Cohort 24

25The cohort included consecutive patients with Boston Scientific PMs implanted for SND from 2012-2021 at 4 hospitals (Cleveland Clinic in the Unites States, University of 2627Occupational and Environmental Health, Japan, Kyushu Rosai Hospital, and JCHO Kyushu Hospital in Japan). Patients were excluded if they had single chamber or biventricular PMs, 28atrial fibrillation (AF) before PM implantation or detected device-determined AHREs 29detection during the first 3 months after implantation. 30

Data were analyzed retrospectively. The study was approved by the Institutional 3132Review Board of the Cleveland Clinic, University of Occupational and Environmental Health,

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

- Japan, Kyushu Rosai Hospital, and JCHO Kyushu Hospital. 1
- $\mathbf{2}$ Heart Rate Score (HRSc) and Baseline Period

HRSc was defined, as previously described, as the percent of all paced and sensed atrial 3

- events in the most populated 10-bpm rate histogram bin of the CIED, shown in Figure 1.<sup>4</sup> 4
- HRSc, used in all analyses, was determined from remote interrogation data from the  $\mathbf{5}$
- 6 dual-chamber PM during the baseline period (the first 3 months after PM implantation). The
- 7 HRSc, calculated at the last transmission during the baseline period, was designated the
- 8 initial HRSc.
- 9 Outcome

10 The endpoint was device-determined AHREs after the baseline period. The endpoint for

- 11 AHREs was considered >1% of atrial beats  $\geq$ 170 beats/min recorded by the PM.
- 12Follow-up Data Analysis

The occurrence of AHREs was examined using stored remote monitoring data and 1314tracked during follow-up periods. The relationship between the initial HRSc and occurrence 15of device-determined AHREs was assessed.

16**Statistical Analysis** 

17Continuous variables were expressed as mean±standard deviation (SD), median (interquartile range, IQR: 25<sup>th</sup>-75<sup>th</sup>), or range, depending on the distribution of data, whereas 18categorical variables were expressed as counts and percentages. The optimal HRSc for 1920predicting device-determined AHREs was chosen to be 80% for AHREs based on J-statistics (Figure 2). Kaplan-Meier analyses evaluated freedom from AHREs after the baseline period 21for the two initial HRSc groups. Log-rank tests were performed to compare group classified 2223by initial HRSc. Variables with P values <0.05 after single variable analysis were entered into a multiple variable regression analysis to assess if there is an independent predictor of 24AHREs. P<0.05 was considered statistically significant. All statistical analysis were 2526performed using JMP version 15.2.0 (SAS Institute Inc., Cary, NC). 27Results

28Subjects Demographics

29A total of 310 consecutive patients were enrolled. Patients who had atrial fibrillation before PM implantation or device-determined AHREs in the first three months 30 (n=174) were excluded. The remaining 136 were followed for a median of 48.9 (IQR, 31

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

### 25.8-50.4) months. 1

 $\mathbf{2}$ Patient characteristics are listed in Table 1. The mean patient age was  $75\pm10$  years; 3 57 (41.9%) were male. Almost 50% of patients were Asian and 40% were European 4 American. No patients were prescribed anti-arrhythmic drugs. The mean left ventricular  $\mathbf{5}$ ejection fraction (LVEF) and left atrial diameter (LAD) by echocardiogram were  $62\pm7$  % and 6 41±7 mm, respectively. The atrial lead was placed in the right atrium appendage in almost all 7patients. The ventricular lead was implanted in right ventricular septum in approximately 8 two-thirds. 9 Pacemaker Programming and Interrogation Data 10 Pacemaker programming at the time of implantation is shown in Table 2. 11 Rate-responsive pacing was programmed in 70% of patients. Atrial sensitivity was programmed to a mean of 0.4±0.1 mV and the lower rate limit (LRL) was programmed to 60 1213bpm in 124/136 (91.2%) patients. The cumulative percent of RA and RV pacing (%RA pacing and %RV pacing) during the baseline period were a mean of 57±32 %, and 13±27 %, 14respectively. 15Heart Rate Score 16The initial HRSc was calculated at a median of 51 days (IQR, 7-84) after 1718pacemaker implantation. The median value of the HRSc was 73% (IQR, 55-86%). 19Outcome Over a median of 48.9 months (IQR, 25.8-50.4 months), 28/136 (21%) subjects 20experienced the endpoint of >1% AHREs. Subjects with an initial HRSc  $\geq$ 80% had a higher 21incidence of AHREs (Kaplan-Meier rate of 40%) versus those with an initial HRSc <80% 2223(Kaplan-Meier rate of 24%) through the 90.0 months during post-baseline follow-up. (log-rank P =0.01) (Figure 3). 24Association of Heart Rate Score and Percent of Right Atrial Pacing 2526Figure 4 shows a positive correlation between %RA pacing during the baseline period and initial HRSc ( $R^2$ =0.725, P<0.0001) for all patients. Patients were analyzed 27additionally by the %RA pacing and rate-response (ON or OFF). HRSc was plotted against 2829RA pacing (Figures 5 and 6). In all 7 patients with high %RA pacing (pacing  $\geq$ 70%) and no 30 rate response (OFF), HRSc was high ( $\geq 80\%$ ). For those with rate response ON, with RA

- pacing  $\geq$ 70%, 14/54 patients had HRSc <80% (Figure 5). In patients with mid and low %RA 31
- 32pacing (<70%), the distribution of HRSc did not differ between those with rate response ON

Heart Rate Score and Atrial High-Rate Episodes

February 5, 2024

and OFF (Figure 6). 1

 $\mathbf{2}$ Predictors for Incidence of Atrial High-Rate Episode

3 By multivariable analysis, the initial HRSc (HR: 2.84, 95% CI: 1.17-6.92; P=0.02)

and male sex (HR: 2.55, 95% CI: 1.15-6.19; P=0.04) were the only independent predictors of 4

AHREs incidence (Table 3).  $\mathbf{5}$ 

### 6 Discussion

7 We found that the initial HRSc  $\geq$ 80 %, calculated within 3 months after 8 dual-chamber PM implantation for SND, independently predicted new-onset, device defined, AHREs in subsequent follow-up. This report is the first to demonstrate a relationship 9 between HRSc and device-detected AHREs in this population. Subjects with an initial HRSc 10  $\geq$ 80% had an increased risk of AHREs. This analysis held true over the 48.9-month 11 12follow-up, after adjustment for risk factors for AHREs including: age, race, histories of hypertension, diabetes mellitus, coronary artery disease, cardiomyopathy, LVEF, 13LAD, %RA/RV pacing, and rate-responsive pacing. Despite a positive correlation 14between %RA pacing and HRSc for patients dependent on RA pacing, more than one-quarter 15with rate-responsive pacing had HRSc <80%; those without rate-responsive pacing all had 1617HRSc  $\geq 80\%$ .

18Our study indicates that a high initial HRSc ( $\geq$ 80%) predicts AHREs recorded after 19PM implantation for SND independently. Currently no established indicator from electrocardiograms or device interrogation has been shown to predict subsequent 20development of AHREs. Although our prior report<sup>7</sup> indicated that the HRSc predicts 21subsequent AHREs in PM patients in a large de-identified database, clinical parameters 2223including PM indication could not be determined. Therefore, we investigated the relationship 24between initial HRSc and subsequent AHREs focusing on PM patients implanted for SND in 25the current study.

26Our results demonstrate that HRSc predicts pacemaker detected AHREs. It is not clear that this correlates directly to clinical AF. However, in our prior report<sup>7</sup>, the incidence 27of AHREs defined by >1% of atrial beats  $\geq$  170 bpm correlated with the incidence of mode 2829switch episodes  $\geq$ 24 hours which is likely to represent substantial paroxysmal or persistent AF. 30

Age, gender, hypertension, diabetes mellitus, ischemic heart disease, 3132pharmacologic therapy, left atrial dilatation, and LVEF, are well known risk factors for

### Heart Rate Score and Atrial High-Rate Episodes *February* 5, 2024

AF.<sup>8-11</sup> In our study, HRSc predicted AHREs independent of other risk factors. 1 Interestingly, however, male gender also predicted AHREs. This result is consistent with  $\mathbf{2}$ community-based ARIC (Atherosclerosis Risk In Communities) study that showed higher 3 incidence of AF in males than females.<sup>12</sup> In pacemaker patients with SND, high %RV pacing 4 is found to be associated with an increased AF.<sup>13-15</sup> In addition, the association between %RA  $\mathbf{5}$ pacing and AF has been also identified.<sup>16,17</sup> 6

 $\overline{7}$ In the current study, the median HRSc of 73% in PM patients with SND was higher than prior reports.<sup>2,7</sup> This result indicates that our study patients have severe chronotropic 8 incompetence. Patients with little or no spontaneous heart rate change above the LRL have a 9 high HRSc<sup>1</sup>. In addition, the optimal HRSc cut-point to predict device-determined AHREs 10 was found to be  $\geq$ 80%. Notably, this optimal cut-point is different from HRSc  $\geq$ 70% for 11 predicting mortality in patients with ICDs or CRT-Ds.<sup>3,4</sup> 12

13Rate-responsive pacing can decrease HRSc in patients with sinus node dysfunction 14who pace predominantly at the LRL and have a high HRSc (Figure 5). On the other hand, for patients with SND who have less chronotropic incompetence, rate-responsive RA pacing may 1516be less likely affect HRSc (Figure 6). Rate responsive pacing may be excessive or even harmful for those who have chronotropic competence.<sup>3</sup> Rate-responsive pacing may be best 17reserved for those with high baseline HRSc. However, LRL programming affects %RA 1819pacing and HRSc. A high LRL can override the resting intrinsic rate resulting in an increase in %RA pacing and subsequently increase in HRSc. Conversely, programming a lower LRL 20may decrease %RA pacing and lower HRSc. Most subjects in this study were programmed to 2122an LRL of 60 but prior data showed that lower LRL programming improved survival in a large database of CRT-D subjects.<sup>18</sup> Further research is needed to assess the relationships of 23LRL, AHREs, %RA pacing and HRSc. 24

**Study Limitations** 25

26This was a retrospective analysis and therefore, may be affected by unknown 27confounders. We were unable to assess the impact of rate responsive pacing on AHREs. The present study also does not answer whether lowering HRSc with pacemaker programming 28affects AHREs. The population was not large enough to determine relationships of HRSc to a 2930 higher percentage of AHREs or episodes that could become persistent AF.

31Conclusion

In patients undergoing PM implant for SND, HRSc≥80% independently predicted 32device-determined AHREs in long-term follow-up. As initial HRSc predicts AHREs in this 33

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

- population, this parameter may have prognostic and therapeutic implications. 1
- $\mathbf{2}$ Acknowledgements:
- Bruce L. Wilkoff, MD passed away before submitting this manuscript and authors express 3
- our sincerest condolence to him and sincerely appreciate his incredible leadership, he gave to 4
- see this project completed. And the authors sincerely appreciate Hiroyuki Takatsu, MD, of  $\mathbf{5}$
- 6 Kyushu Rosai Hospital, and Kan Kikuchi, MD, of JCHO Kyushu Hospital for obtaining
- 7 patient's demographic and HRSc data.
- 8
- 9 Sources of Funding: None
- 10
- 11 Disclosures:
- 12KH and RK: have nothing to declare.
- HA: Research Grant: Boston Scientific, Medtronic, Abbott 13
- BO: Member of a DSMB sponsored by AstraZeneka 14
- ADS: Consultant: VivaQuant, CardioSignal 15
- PWJ, NW, and DP are salaried employees of Boston Scientific. 16
- 17BLW: Consultant and Speaker: Boston Scientific, Medtronic, Abbott, Biotronik
- 18GYHL: Consultant and speaker: BMS/Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Anthos.
- 19He is a National Institute for Health and Care Research (NIHR) Senior Investigator and
- 20co-principal investigator of the AFFIRMO project on multimorbidity in AF, which has
- 21received funding from the European Union's Horizon 2020 research and innovation
- programme under grant agreement No 899871. 22

- 24Data Availability: The data underlying this article will be shared on reasonable request to the
- corresponding authors. 25
- 26
- 27

Heart Rate Score and Atrial High-Rate Episodes

February 5, 2024

References 1

- Sharma A, Richards M, Olshansky B, Wold N, Jones P, Perschbacher D, Wilkoff BL.  $\mathbf{2}$ 1.
- Heart rate score, a measure related to chronotropic incompetence in pacemaker patients. 3
- 4 Heart Rhythm O2. 2021;2:124-131.
- 2. Gopinathannair R, Sharma A, Jones P, English C, Furmanek S, Olshansky B. Heart rate  $\mathbf{5}$
- score and outcomes in ICD patients: insights from the prospective randomized INTRINSIC 6
- RV trial. J Interv Card Electrophysiol. 2022;64:87-93. 7
- Olshansky B, Richards M, Sharma A, Wold N, Jones P, Perschbacher D, Wilkoff BL. 8 3.
- Survival after rate-responsive programming in patients with cardiac resynchronization 9
- therapy-defibrillator implants is associate with a novel parameter: The Heart rate score. Circ 10
- Arrhythm Electrophysiol. 2016;9:e003806. 11
- 4. Wilkoff BL, Richards M, Sharma A, Wold N, Jones P, Perschbacher D, Olshansky B. A 12
- 13device histogram-based simple predictor of mortality risk in ICD and CRT-D patients: the
- heart rate score. Pacing Clin Electrophysiol. 2017;40:333-343. 14
- Kirchof P, Toennis T, Goette A, Camm AJ, Diener HC, Becher N, Becher N, Bertaglia E, 155.
- 16Blomstrom Lundqvist C, Borlich M, et al: NOAH-AFNET 6. Anticoagulation with edoxaban in patients with atrial high-rate episodes. N Engl J Med. 2023;389:1167-1179. 17
- 6. Healey JS, Lopes RD, Granger CB, Alings M, Rivard L, McIntyre WF, Atar D, Birnie 18
- 19DH, Boriani G, Camm AJ, et al: ARTESIA investigators. Apixaban for stroke prevention in
- subclinical atrial fibrillation. N Engl J Med. 2023 Nov 12. doi: 10.1056/NEJMoa2310234. 20
- 217. Hayashi K, Abe H, Olshansky B, Sharma AD, Jones PW, Wold N, Perschbacher D,
- 22Kohno R, Richards M, Wilkoff BL. Initial heart rate score predicts new-onset atrial
- tachyarrhythmias in pacemaker patients. Europace. 2023. Aug 2;25:euad242. doi: 23
- 10.1093/europace/euad242.  $\mathbf{24}$
- 258. Himmelreich JCL, Lucassen WAM, Harskamp RE, Aussems C, van Weert HCPM,
- Nielsen MMJ. CHARGE-AF in a national routine primary care electronic health records 26
- database in the Netherlands: validation for 5-year risk of atrial fibrillation and implications 27
- 28for patient selection in atrial fibrillation screening. Open Heart. 2021;8:e001459
- 29Magnussen C, Niiranen TJ, Ojeda FM, Gianfagna F, Blankenberg S, Njølstad I, 9.
- Vartiainen E, Sans S, Pasterkamp G, Hughes M, et al; BiomarCaRE Consortium. Sex 30
- 31difference and similarities in atrial fibrillation epidemiology, risk factors, and mortality in
- 32community cohorts: Results from BiomarCaRE Consortium (Biomarker for cardiovascular
- risk assessment in Europe). Circulation 2017;136:1588-1597. 33
- 34Dittrich HC, Pearce LA, Asinger RW, McBride R, Zabalgoitia M, Pennock GD, Safford 10.
- RE, Rothbart RM, Halperin JL, Hart RG; Left atrial diameter in nonvalvular atrial 35

### Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

- fibrillation: An echocardiographic study. Stroke prevention in atrial fibrillation investigators. 1
- Am Heart J. 1999;137:494-499.  $\mathbf{2}$
- Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, 3 11.
- Parissis J, Laroche C, Piepoli MF, Fonseca C, et al. Epidemiology and one-year outcomes in 4
- patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an  $\mathbf{5}$
- analysis of the ESC Heart Failure long-term registry. Eur J Heart Fail. 2017;19:1574-1585. 6
- $\overline{7}$ Aronis KN, Zhao D, Hoogeveen RC, Alonso A, Ballantyne CM, Guallar E, Jones SR, 12.
- Martin SS, Nazarian S, Steffen BT, et al. Association of lipoprotein(a) levels with incident 8
- atrial fibrillation and ischemic stroke: The ARIC (Atherosclerosis risk in communities) study. 9
- 10 J Am Heart Assoc. 2017;6:e007372. doi: 10.1161/JAHA.117.007372.
- Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, 11 13.
- Lamas GA: Mode Selection Trial investigators. Adverse effect of ventricular pacing on heart 12
- 13failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical
- trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107:2932-2937. 14
- 14. Nielsen JC, Kristensen L, Anderson HR, Mortensen PT, Pedersen OL, Pedersen AK. A 15
- randomized comparison of atrial and dual-chamber pacing in 177 consecutive patients with 16
- sick sinus syndrome: echocardiographic and clinical outcome. J Am Coll Cardiol. 17
- 18 2003;42:614-623.
- 1915. Hayashi K, Kohno R, Fujino Y, Takahashi M, Oginosawa Y, Ohe H, Miyamoto T,
- 20Fukuda S, Araki M, Sonoda S, et al. Pacing from right ventricular septum and development
- of new atrial fibrillation in paced patients with atrioventricular block and preserved left 21
- 22ventricular function. Circ J. 2016;80:2302-2309.
- Elkayam LU, Koehler JL, Sheldon TJ, Glotzer TV, Rosenthal LS, Lamas GA. The 2316.
- influence of atrial and ventricular pacing on the incidence of atrial fibrillation: a 24
- 25meta-analysis. Pacing Clin Electrophysiol. 2011;34:1593-1599.
- Hjotshøj S, Riahi S, Nielsen JC, Skjøth F, Lundbye-Christensen S, Anderson HR; 2617.
- DANPACE Investigators. Does atrial pacing lead to atrial fibrillation in patients with sick 27
- 28sinus syndrome? Insight from DANPACE trial. Europace. 2014;16:241-245.
- Sharma AD, Wilkoff BL, Richards M, Wold N, Jones P, Perschbacher D, Olshansky B. 2918.
- Lower rate limit for pacing by cardiac resynchronization defibrillators: Should lower rate 30
- 31programming be reconsidered? Heart Rhythm. 2021;18:2087-2093.
- 32
- 33

Heart Rate Score and Atrial High-Rate Episodes

*February* 5, 2024

## 

**Figure and Table Legends** 

### $\mathbf{2}$ Figure 1. Example of HRSc



The HRSc was defined as the percent of all paced and sensed atrial event in single most 

populated 10-bpm rate histogram bin. This figure shows an example of HRSc of the patients  $\mathbf{5}$ 

in DDD mode. Here, HRSc is calculated as 74%. 

- HRSc indicates heart rate score.  $\overline{7}$

Heart Rate Score and Atrial High-Rate Episodes

February 5, 2024

### Figure 2. Optimal HRSc for predicting AHREs



J-statistic analysis shows 80% as the optimal HRSc for predicting device-determined AHREs. 

- AHREs, atrial high-rate episodes; HRSc, heart rate score.  $\mathbf{5}$

 $\mathbf{2}$ 

- $\overline{7}$

Heart Rate Score and Atrial High-Rate Episodes

*February* 5, 2024

Figure 3. Survival free from AHREs by HRSc



 $\mathbf{2}$ 

Survival free from AHREs by HRSc Grouping is shown in this Kaplan-Meyer analysis.

Kaplan-Meier analysis shows that subjects with an initial HRSc  $\geq$ 80% had a higher incidence 

of AHREs versus those with an initial HRSc <80%, the primary end point.  $\mathbf{5}$ 

 $\mathbf{7}$ 

HRSc indicates heart rate score; AHREs, atrial high-rate episodes.

Heart Rate Score and Atrial High-Rate Episodes *February* 5, 2024

Figure 4. Heart Rate Score and % RA pacing (Correlation by continuous measures)



 $\mathbf{2}$ 

 $\mathbf{5}$ 

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

Figure 5. Heart rate score and %RA pacing (%RA pacing  $\geq$ 70%, N=61)



 $\mathbf{2}$ 

**Baseline %RA pacing** 

In the patients with %RA pacing  $\geq$ 70%, when the rate response was OFF (red point, N=7), all HRSc was  $\geq$ 80%. On the other hand, when the rate response was ON (blue point, N=54), 14 /54 patients had HRSc <80%  $\mathbf{5}$  $\overline{7}$ 

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024



1 Figure 6. Heart rate score and %RA pacing (%RA pacing <70%, N=75)

 $\mathbf{2}$ 



cases with rate response ON (blue point, N=40) and OFF (red point, N=35). 4

HRSc indicates heart rate score; RA, right atrium.  $\mathbf{5}$ 

### Heart Rate Score and Atrial High-Rate Episodes

February 5, 2024

#### 1 Table 1. Patient characteristics

Demographics				
Age (years)	$75 \pm 10$			
Gender: Male, n (%)	57 (41.9)			
Race, n (%)				
Asian	73 (53.7)			
European American	56 (41.2)			
African American	6 (4.4)			
Multi-racial	1 (0.7)			
Medical history, n (%)				
Hypertension	76 (55.9)			
Diabetes mellitus	24 (17.6)			
Ischemic heart disease	14 (10.3)			
Cardiomyopathy	10 (7.3)			
Medication regimen, n (%)				
Angiotensin converting enzyme inhibitor	6 (4.4)			
Angiotensin receptor blocker	26 (19.1)			
β-blocker	19 (14.0)			
Anti-arrhythmic drugs	0 (0)			
Anticoagulant	6 (4.4)			
Echocardiographic measurements				
Left ventricular ejection fraction, %	$62 \pm 7$			
Left atrial diameter, mm	$41 \pm 7$			
Pacing site, n (%)				
Right atrium				
Appendage	131 (96.3)			
Low septum	5 (3.7)			
Right ventricle				
Apex	47 (34.6)			
Septum	89 (65.4)			

Continuous variables were expressed as mean ± standard deviation (SD); Categorical data are  $\mathbf{2}$ 

3 presented as number (percentage).

Heart Rate Score and Atrial High-Rate Episodes February 5, 2024

Pacing mode	
DDD	42 (30.9)
DDDR	93 (68.4)
DDIR	1 (0.7)
Rate responsive pacing programming ON	94 (69.1)
Dual sensors (Accelerometer and Minute ventilation)	63
Single sensors	31
Accelerometer	11
Minute ventilation	20
Atrial sensitivity	$0.4 \pm 0.1$
Pacing rate, ppm	
Lower rate limit	$59 \pm 4$
Max tracking rate limit	$124 \pm 11$
Atrioventricular interval, ms	
Sensed	$219\pm74$
Paced	$238\pm62$
Cumulative% of	
Atrial paced	$57 \pm 32$
Ventricular paced	$13 \pm 27$

#### 1 Table 2. Pacemaker programming and interrogation data

 $\mathbf{2}$ HR indicates heart rate; RV, right ventricle; DDD, non-rate responsive pacing; DDDR, DDIR,

rate responsive pacing. 3

# 1 Table 3. Predictors for AHREs

	Univariate analysis		Multivariable	Multivariable analysis	
	OR (95% CI)	P value	OR (95% CI)	P value	
Age, per year	0.99 (0.96-1.04)	0.97			
Gender, male	2.63 (1.12-6.17)	0.03	2.55 (1.05-6.19)	0.04	
Hypertension	1.28 (0.55-3.00)	0.56			
Diabetes mellitus	0.50 (0.14-1.80)	0.29			
Coronary artery disease	1.06 (0.27-4.08)	0.94			
Cardiomyopathy	0.96 (0.19-4.80)	0.96			
β-blocker	1.03 (0.31-3.34)	0.96			
Angiotensin receptor blocker	0.44 (0.12-1.60)	0.21			
European American (Race) vs. Japanese	2.03 (0.85-4.86)	0.11			
LV ejection fraction, per 1%	0.96 (0.90-1.02)	0.23			
Left atrium diameter, mm	1.02 (0.95-1.10)	0.56			
Rate response On	3.26 (1.05-10.08)	0.04	2.77 (0.86-8.91)	0.09	
Lower rate limit, ppm	1.05 (0.93-1.19)	0.43			
%RA pacing	3.91 (0.94-16.27)	0.06			
%RV pacing	1.86 (0.45-7.68)	0.39			
Initial heart rate score $\ge 80\%$	3.22 (1.37-7.61)	0.007	2.84 (1.17-6.92)	0.02	

2 AHREs = Atrial high-rate episodes; RA = Right atrium; RV = Right ventricle; OR = Odds Ratio; CI = Confidence interval.